Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-09 4:17 pm Purchase | 2022-12-31 | 13G | Cepton, Inc. CPTN | Point72 Asset Management, L.P. | 181,523 1.200% | 181,523 (New Position) | Filing History |
| 2023-02-23 7:43 pm Purchase | 2023-02-22 | 13G | Inari Medical, Inc. NARI | Point72 Asset Management, L.P. | 2,795,352 5.200% | 2,795,352 (New Position) | Filing History |
| 2023-02-17 4:35 pm Purchase | 2023-02-16 | 13G | Iovance Biotherapeutics, Inc. IOVA | Point72 Asset Management, L.P. | 8,114,890 5.000% | 8,114,890 (New Position) | Filing History |
| 2023-02-14 4:27 pm Purchase | 2022-12-31 | 13G | Prometheus Biosciences, Inc. RXDX | Point72 Asset Management, L.P. | 3,114,107 6.700% | 1,131,546 (+57.07%) | Filing History |
| 2023-02-14 4:25 pm Purchase | 2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Point72 Asset Management, L.P. | 3,515,356 7.100% | 116,695 (+3.43%) | Filing History |
| 2023-02-14 4:23 pm Purchase | 2022-12-31 | 13G | GRITSTONE BIO INC GRTSQ | Point72 Asset Management, L.P. | 7,702,831 9.200% | 1,094,273 (+16.56%) | Filing History |
| 2023-02-14 4:23 pm Sale | 2022-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 193,400 5.400% | -22,502 (-10.42%) | Filing History |
| 2023-02-14 4:22 pm Purchase | 2022-12-31 | 13G | FibroGen, Inc. FGEN | Point72 Asset Management, L.P. | 251,266 6.700% | 64,622 (+34.62%) | Filing History |
| 2023-02-14 4:22 pm Purchase | 2022-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 2,086 5.300% | 2,086 (New Position) | Filing History |
| 2023-02-14 4:21 pm Sale | 2022-12-31 | 13G | AnaptysBio, Inc. ANAB | Point72 Asset Management, L.P. | 2,124,200 7.500% | -157,000 (-6.88%) | Filing History |
| 2023-02-14 4:20 pm Purchase | 2022-12-31 | 13G | Abeona Therapeutics Inc. ABEO | Point72 Asset Management, L.P. | 1,150,648 7.400% | 189,778 (+19.75%) | Filing History |
| 2023-02-14 4:20 pm Purchase | 2022-12-31 | 13G | Eos Energy Enterprises, Inc. EOSE | Point72 Asset Management, L.P. | 5,535,030 6.700% | 2,493,265 (+81.97%) | Filing History |
| 2023-02-14 4:19 pm Sale | 2022-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA | Point72 Asset Management, L.P. | 69,450 0.100% | -1,984,767 (-96.62%) | Filing History |
| 2023-02-14 4:19 pm Sale | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Point72 Asset Management, L.P. | 1,178,501 1.900% | -1,828,637 (-60.81%) | Filing History |
| 2023-02-14 4:18 pm Sale | 2022-12-31 | 13G | Health Catalyst, Inc. HCAT | Point72 Asset Management, L.P. | 1,920,253 3.500% | -864,631 (-31.05%) | Filing History |
| 2023-02-14 4:18 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 30,441 1.300% | -23,999 (-44.08%) | Filing History |
| 2023-02-14 4:17 pm Unchanged | 2022-12-31 | 13G | Cepton, Inc. CPTN | Point72 Asset Management, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:17 pm Sale | 2022-12-31 | 13G | uniQure N.V. QURE | Point72 Asset Management, L.P. | 1,745,461 3.700% | -1,866,230 (-51.67%) | Filing History |
| 2023-02-14 4:16 pm Sale | 2022-12-31 | 13G | TRICIDA INC TCDAQ | Point72 Asset Management, L.P. | 167,509 0.300% | -3,117,394 (-94.90%) | Filing History |
| 2023-02-14 4:15 pm Sale | 2022-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC | Point72 Asset Management, L.P. | 30,702 0.100% | -2,037,172 (-98.52%) | Filing History |